Memory B cell responses induced by pneumococcal conjugate vaccine schedules with fewer doses: analysis of a randomised-controlled trial in Viet Nam.
Humans
Pneumococcal Vaccines
/ immunology
Vietnam
Infant
Streptococcus pneumoniae
/ immunology
Pneumococcal Infections
/ prevention & control
Immunization Schedule
Memory B Cells
/ immunology
Female
Vaccines, Conjugate
/ immunology
Male
Antibodies, Bacterial
/ immunology
Vaccination
/ methods
Child, Preschool
Immunoglobulin G
/ blood
Serogroup
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
14 Aug 2024
14 Aug 2024
Historique:
received:
27
05
2024
accepted:
06
08
2024
medline:
14
8
2024
pubmed:
14
8
2024
entrez:
13
8
2024
Statut:
epublish
Résumé
The use of pneumococcal conjugate vaccine (PCV) schedules with fewer doses are being considered to reduce costs and improve access, particularly in low- and middle-income countries. While several studies have assessed their immunogenicity, there are limited data on their potential for long-term immune protection, as assessed by pneumococcal serotype-specific memory B cell (B
Identifiants
pubmed: 39138203
doi: 10.1038/s41467-024-51413-7
pii: 10.1038/s41467-024-51413-7
doi:
Substances chimiques
Pneumococcal Vaccines
0
13-valent pneumococcal vaccine
0
Vaccines, Conjugate
0
Antibodies, Bacterial
0
10-valent pneumococcal conjugate vaccine
0
Immunoglobulin G
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
6968Subventions
Organisme : Bill & Melinda Gates Foundation
ID : INV-008627
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Global Burden of Disease Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect. Dis. 18, 1191–1210 (2018).
International Vaccine Access Centre. VIEW-hub (John Hopkins Bloomberg School of Public Health, 2024). Available from: www.view-hub.org .
International Vaccine Access Centre. Pneumonia and diarrhea progress report 2023 (John Hopkins Bloomberg School of Public Health; 2023).
Hanquet, G. et al. Serotype replacement after introduction of 10-valent and 13-valent pneumococcal conjugate vaccines in 10 countries, Europe. Emerg. Infect. Dis. 28, 137–138 (2022).
doi: 10.3201/eid2801.210734
pubmed: 34932457
World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper - February 2019. World Health Org. Weekly Epidemiological Record 8, 85–104 (2019).
Flasche, S. et al. The potential for reducing the number of pneumococcal conjugate vaccine doses while sustaining herd immunity in high-income countries. PLoS Med. 12, e1001839 (2015).
doi: 10.1371/journal.pmed.1001839
pubmed: 26057994
pmcid: 4461163
Ladhani, S. N., Andrews, N. & Ramsay, M. E. Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK. Lancet Infect. Dis. 21, e93–e102 (2021).
doi: 10.1016/S1473-3099(20)30492-8
pubmed: 33129426
Bertran, M. et al. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Lancet Infect. Dis. 24, 546–556 (2024).
doi: 10.1016/S1473-3099(23)00706-5
pubmed: 38310905
Temple, B. et al. Efficacy against pneumococcal carriage and the immunogenicity of reduced-dose (0 + 1 and 1 + 1) PCV10 and PCV13 schedules in Ho Chi Minh City, Viet Nam: a parallel, single-blind, randomised controlled trial. Lancet Infect. Dis. 23, 933–944 (2023).
doi: 10.1016/S1473-3099(23)00061-0
pubmed: 37062304
pmcid: 10371874
Licciardi, P. V. et al. Immunogenicity of alternative ten-valent pneumococcal conjugate vaccine schedules in infants in Ho Chi Minh City, Vietnam: results from a single-blind, parallel-group, open-label, randomised, controlled trial. Lancet Infect. Dis. 21, 1415–1428 (2021).
doi: 10.1016/S1473-3099(20)30775-1
pubmed: 34171233
pmcid: 8461081
Papadatou, I., Tzovara, I. & Licciardi, P. V. The role of serotype-specific immunological memory in pneumococcal vaccination: current knowledge and future prospects. Vaccines 7, 13 (2019).
doi: 10.3390/vaccines7010013
pubmed: 30700048
pmcid: 6466264
Jochems, S. P., Weiser, J. N., Malley, R. & Ferreira, D. M. The immunological mechanisms that control pneumococcal carriage. PLoS Pathog. 13, e1006665 (2017).
doi: 10.1371/journal.ppat.1006665
pubmed: 29267378
pmcid: 5739485
Pennington, S. H. et al. Polysaccharide-specific memory B cells predict protection against experimental human pneumococcal carriage. Am. J. Respir. Crit. Care Med. 194, 1523–1531 (2016).
doi: 10.1164/rccm.201512-2467OC
pubmed: 27403678
pmcid: 5215029
Chapman, T. J., Pichichero, M. E. & Kaur, R. Comparison of pneumococcal conjugate vaccine (PCV-13) cellular immune responses after primary and booster doses of vaccine. Hum. Vaccin Immunother. 16, 3201–3207 (2020).
doi: 10.1080/21645515.2020.1753438
pubmed: 32401658
pmcid: 8641578
Truck, J. et al. Divergent memory B cell responses in a mixed infant pneumococcal conjugate vaccine schedule. Pediatr. Infect. Dis. J. 36, e130–e135 (2017).
doi: 10.1097/INF.0000000000001497
pubmed: 28027283
Truck, J. et al. Memory B cell response to a PCV-13 booster in 3.5 year old children primed with either PCV-7 or PCV-13. Vaccine 35, 2701–2708 (2017).
doi: 10.1016/j.vaccine.2017.03.079
pubmed: 28392142
Muema, D. M. et al. 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) induces memory B cell responses in healthy Kenyan toddlers. Clin. Exp. Immunol. 181, 297–305 (2015).
doi: 10.1111/cei.12637
pubmed: 25845628
pmcid: 4516445
Higgins, R. A. et al. Immunogenicity and impact on nasopharyngeal carriage of a single dose of PCV10 given to Vietnamese children at 18 months of age. Lancet Reg. Health West Pac. 16, 100273 (2021).
pubmed: 34590071
pmcid: 8453212
Alicino, C. et al. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: a systematic review and meta-analysis. Vaccine 35, 5776–5785 (2017).
doi: 10.1016/j.vaccine.2017.09.005
pubmed: 28911902
Ngocho, J. S. et al. Effectiveness of pneumococcal conjugate vaccines against invasive pneumococcal disease among children under five years of age in Africa: a systematic review. PLoS One 14, e0212295 (2019).
doi: 10.1371/journal.pone.0212295
pubmed: 30779801
pmcid: 6380553
Kwambana-Adams, B. A. et al. An outbreak of pneumococcal meningitis among older children (≥5 years) and adults after the implementation of an infant vaccination programme with the 13-valent pneumococcal conjugate vaccine in Ghana. BMC Infect. Dis. 16, 575 (2016).
doi: 10.1186/s12879-016-1914-3
pubmed: 27756235
pmcid: 5070171
Lourenco, J. et al. Determinants of high residual post-PCV13 pneumococcal vaccine-type carriage in Blantyre, Malawi: a modelling study. BMC Med. 17, 219 (2019).
doi: 10.1186/s12916-019-1450-2
pubmed: 31801542
pmcid: 6894346
Andrews, N. J. et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect. Dis. 14, 839–846 (2014).
doi: 10.1016/S1473-3099(14)70822-9
pubmed: 25042756
Mueller, J. E. et al. Pneumococci in the African meningitis belt: meningitis incidence and carriage prevalence in children and adults. PLoS One 7, e52464 (2012).
doi: 10.1371/journal.pone.0052464
pubmed: 23285051
pmcid: 3527509
Jochems, S. P. et al. Innate and adaptive nasal mucosal immune responses following experimental human pneumococcal colonization. J. Clin. Invest. 129, 4523–4538 (2019).
doi: 10.1172/JCI128865
pubmed: 31361601
pmcid: 6763269
Swarthout, T. D. et al. Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study. Lancet Infect. Dis. 22, 1737–1747 (2022).
doi: 10.1016/S1473-3099(22)00438-8
pubmed: 36029796
pmcid: 10555849
Davis, S. M., Deloria-Knoll, M., Kassa, H. T. & O’Brien, K. L. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 32, 133–145 (2013).
doi: 10.1016/j.vaccine.2013.05.005
pubmed: 23684824
Chard, A. N., Gacic-Dobo, M., Diallo, M. S., Sodha, S. V. & Wallace, A. S. Routine vaccination coverage - worldwide, 2019. Morb. Mortal. Wkly Rep. 69, 1706–1710 (2020).
doi: 10.15585/mmwr.mm6945a7
Wahl, B. et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob. Health 6, e744–e757 (2018).
doi: 10.1016/S2214-109X(18)30247-X
pubmed: 29903376
pmcid: 6005122
Crotty, S., Aulbert, R. D., Glidewell, J. & Ahmed, R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J. Immunol. Methods 286, 111–122 (2004).
doi: 10.1016/j.jim.2003.12.015
pubmed: 15087226
Broketa, M. & Bruhns, P. Single-cell technologies for the study of antibody-secreting cells. Front. Immunol. 12, 821729 (2021).
doi: 10.3389/fimmu.2021.821729
pubmed: 35173713
Temple, B. et al. Simplified 0+1 and 1+1 pneumococcal vaccine schedules in Ho Chi Minh City, Vietnam: protocol for a randomised controlled trial. BMJ Open 11, e056505 (2021).
doi: 10.1136/bmjopen-2021-056505
pubmed: 34845082
pmcid: 8634020
Licciardi, P. V. et al. No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine. J. Allergy Clin. Immunol. 137, 1772–1779 (2016).
doi: 10.1016/j.jaci.2015.12.1303
pubmed: 26825000
pmcid: 4899320
Balloch, A., Licciardi, P. V., Leach, A., Nurkka, A. & Tang, M. L. Results from an inter-laboratory comparison of pneumococcal serotype-specific IgG measurement and critical parameters that affect assay performance. Vaccine 28, 1333–1340 (2010).
doi: 10.1016/j.vaccine.2009.11.011
pubmed: 19932671